MacroGenics, Inc.

President and Chief Financial Officer of Microgenics. Please proceed.

Thank you, Operator. Good afternoon and welcome to Microgenics Conference Call to discuss our fourth quarter and full year 2024 financial and operational results. For anyone who has not had the chance to review the results, we've issued a press release this afternoon outlining today's announcements. This release is available under the Investors tab on our website at macrogenics.com. You may also listen to this conference call via webcast on our website, where it will be archived for 30 days beginning approximately two hours after the call is completed. I'd like to alert listeners that today's discussion will include statements about the company's future expectations, plans, and prospects that constitute forelooking statements for purposes of a safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forelooking statements. as a result of various important factors, including those discussed in the risk factor section of our annual, quarterly, and current reports filed with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change except to the extent required by applicable law. During today's call, I will be joined by Dr. Scott Koenig, President and Chief Executive Officer of Macrogenics, and Dr. Steven Eck, our Senior Vice President, Clinical Development and Chief Medical Officer. And now, I'd like to turn the call over to Scott.

Thank you, Jim. I'd like to welcome everyone participating via conference call and webcast today. 2024 was an important year for Macrogenics, as we achieved several significant clinical development milestones and are well positioned to build upon that momentum in 2025. We have a diverse and promising clinical portfolio, and we look forward to a year of continued progress. On today's call, we will provide key updates on our business and clinical programs. I'll now turn it over to Steven to discuss those clinical updates.